DSIP is a short peptide first identified in the 1970s and named delta sleep-inducing peptide after a proposed role in promoting delta-wave sleep. The name records what researchers hoped it did at the time, which is not the same as what was later demonstrated.

Does DSIP work for sleep?

The evidence is old and thin. The randomised trial closest to the marketed use looked at DSIP in chronic insomniacs and was published in 1992. There has been very little clinical work since, and nothing recent that would settle the question either way.

Why is there so little recent research on DSIP?

We can only report the pattern, not the reason. Publication peaked in the late 1980s at over 200 papers in a decade and has fallen to eleven since 2015. Fields wind down for many reasons, but a compound whose research largely stopped is a different proposition from one whose evidence is still accumulating.

What is the DSIP dosage?

The clinical studies are decades old and were run in specific research settings rather than as consumer sleep protocols. We report doses where a study establishes one for the use in question, and here the relevant study is a 1992 insomnia trial, not a basis for a modern protocol.

It is not approved for human use. It is sold through research-chemical channels, where the contents of the vial are not verified by anyone.

Research peptides

DSIP: A Sleep Peptide Whose Research Mostly Stopped in the 1990s

DSIP has 519 papers behind it and 11 of them since 2015. The closest trial to how it is sold today ran in 1992. The name is doing most of the persuading.

Written bySebastian Hunter, Founder and Editor

Published August 23, 2026

Start here

Plain English

DSIP stands for delta sleep-inducing peptide, a name given on the basis of an early proposed role rather than a proven one. It was researched heavily in the 1980s, and that research has been winding down ever since. The trial closest to how it is sold today was published in 1992.

519 papers in total. Eleven of them published since 2015.
The name describes a hypothesis from the 1970s, not a demonstrated effect.
Not approved for human use; sold as a research chemical.

Most of what is wrong with how DSIP gets sold is contained in its name.

Delta sleep-inducing peptide. It sounds like a finding. It is a label attached in the 1970s on the basis of a proposed role, and it has been doing the persuasive work in the marketing ever since.

The literature has a shape, and the shape is the story

DSIP papers on PubMed, by decade of publication

1975 – 1984
107
1985 – 1994peak
233
1995 – 2004
114
2005 – 2014
54
2015 – 2026the last twelve years
11

Counted August 2026. 519 records in total. This is not a field where evidence is accumulating - it is one that peaked in the late 1980s and has been winding down for thirty years.

That curve is unusual on this site. Most research peptides we cover are recent and under-studied. DSIP is the opposite: extensively studied, a long time ago, by a field that has largely moved on.

The trials, and how close they get to the marketed use

Six records are tagged as randomised trials. Reading them, only one is really about what DSIP is sold for:

Effects of DSIP on the sleep of chronic insomniacs Bes 1992 - Bes F, Hofman W, Schuur J et al. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-7. (opens PubMed in a new tab) — the closest to the marketed use, published in 1992.
Effects on arginine-related endocrine measures Chiodera 1994 - Chiodera P, Volpi R, Capretti L et al. Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men. Horm Res. 1994;42(6):267-72. (opens PubMed in a new tab) — hormonal, not sleep outcomes.
Glucocorticoid replacement and REM sleep García-Borreguero 2000 - García-Borreguero D, Wehr TA, Larrosa O et al. Glucocorticoid replacement is permissive for rapid eye movement sleep and sleep consolidation in patients with adrenal insufficiency. J Clin Endocrinol Metab. 2000;85(11):4201-6. (opens PubMed in a new tab) — DSIP features in the design rather than being the intervention on trial.
DSIP altering bispectral index Pomfrett 2009 - Pomfrett CJ, Dolling S, Anders NR et al. Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia. Eur J Anaesthesiol. 2009;26(2):128-34. (opens PubMed in a new tab) — an anaesthesia-monitoring context, a long way from taking something before bed.

So the honest summary: one randomised trial in the right population, from three decades ago, and a scattering of work that touches the compound in other contexts.

Dose

We report doses where a study establishes one for the use in question. Here the relevant study is a 1992 insomnia trial run in a research setting, and the compound has had almost no clinical attention since.

Turning that into a modern bedtime protocol would mean pretending three decades of silence had not happened.

Status

US legal status - Research use only · not for human use

Sold for laboratory research use only. Not approved by the FDA for human use, and cannot be lawfully marketed as a supplement or a medicine. Products sold this way are not made to pharmaceutical quality standards, and their contents are not verified by anyone.

DSIP is not approved for human use and is sold as a research chemical, which means nobody verifies what is in the vial.

References

Bibliographic detail is fetched from PubMed, not written by us - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than our judgement.